A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Bethge, Nicole ^a,b   Honne, Hilde ^a,b   Andresen, Kim ^a,b   Hilden, Vera ^a,b   Trøen, Gunhild ^a   Liestøl, Knut ^b   Holte, Harald ^b,c   Delabie, Jan ^a   Lind, Guro E ^a,b   Smeland, Erlend B ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; OSTEOGENIC PROTEIN 1; UVOMORULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LRP12 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; B-CELL LYMPHOMA CELL LINE; BMP7 GENE; BMPER GENE; BURKITT LYMPHOMA; CDH1 GENE; CONTROLLED STUDY; DNA METHYLATION; DUSP4 GENE; EPIGENETICS; FOLLICULAR LYMPHOMA; GENE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE IDENTIFICATION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LRP12 GENE; MAJOR CLINICAL STUDY; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PROMOTER REGION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; CASE CONTROL STUDY; CPG ISLAND; DNA SEQUENCE; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; LYMPHOMA, B-CELL; TUMOR CELL LINE;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; LYMPHOMA, B-CELL; PROMOTER REGIONS, GENETIC; ROC CURVE; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL;

EID: 84907278423     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104249     Document Type: Article

References (42)

1. Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid Malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2: 920-933. 10.1038/nri953.
2. De S, Shaknovich R, Riester M, Elemento O, Geng H, et al. (2013) Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. PLoS Genet 9: e1003137. doi:10.1371/journal.pgen.1003137.
3. Esteller M (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298. 10.1038/nrg2005.
4. Ting AH, McGarvey KM, Baylin SB (2006) The cancer epigenome: components and functional correlates. Genes & Development 20: 3215-3231.
5. Jones PA, Baylin SB (2007) The Epigenomics of Cancer. Cell 128: 683-692. doi: DOI: 10.1016/j.cell.2007.01.029.
6. Herman JG, Baylin SB (2003) Gene Silencing in Cancer in Association with Promoter Hypermethylation. N Engl J Med 349: 2042-2054.
7. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428. 10.1038/nrg816.
8. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, et al. (1997) Distinct Patterns of Inactivation of p15INK4B and p16INK4A Characterize the Major Types of Hematological Malignancies. Cancer Res 57: 837-841.
9. Mulero-Navarro S, Esteller M (2008) Epigenetic biomarkers for human cancer: The time is now. Critical Reviews in Oncology/Hematology 68: 1-11. doi: DOI: 10.1016/j.critrevonc.2008.03.001.
10. O'Riain C, O'Shea DM, Yang Y, Le Dieu R, Gribben JG, et al. (2009) Array-based DNA methylation profiling in follicular lymphoma. Leukemia 3(10):1858-66.doi:10.1038/leu.
11. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, et al. (2010) DNA methylation signatures define molecular subtypes of diffuse large B cell lymphoma. Blood 116.20: e81.
12. Daibata M, Nemoto Y, Bandobashi K, Kotani N, Kuroda M, et al. (2007) Promoter Hypermethylation of the Bone Morphogenetic Protein-6 Gene in Malignant Lymphoma. Clin Cancer Res 13: 3528-3535.
13. Uccella S, Cerutti R, Placidi C, Marchet S, Carnevali I, et al. (2009) MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression. Journal of Clinical Pathology 62: 715-723.
14. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, et al, the Lymphoma/Leukemia Molecular Profiling Project (2006) Molecular Diagnosis of Burkitt's Lymphoma. N Engl J Med 354: 2431-2442.
15. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511. 10.1038/35000501.
16. Takai D, Jones PA (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proceedings of the National Academy of Sciences of the United States of America 99: 3740-3745.
17. Andresen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, et al. (2012) Novel target genes and a valid biomarker panel identified for cholangiocarcinoma. Epigenetics 7: 1249-1257.
18. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucl Acids Res 33: 6823-6836.
19. Sudo M, Chong JM, Sakuma K, Ushiku T, Uozaki H, et al. (2004) Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int J Cancer 109: 194-199.
20. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, et al. (2011) RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomarkers 10: 13-26.
21. Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, et al. (2008) Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol 19: 1774-1786.
22. Huang Q, Su X, Ai L, Li M, Fan CY, et al. (2007) Promoter hypermethylation of multiple genes in primary gastric lymphoma. Leukemia and Lymphoma 48: 1988-1996.
23. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, et al. (2000) E-cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 6: 4243-4248.
24. Melki JR, Vincent PC, Brown RD, Clark SJ (2000) Hypermethylation of E-cadherin in leukemia. Blood 95: 3208-3213.
25. Berx G, van Roy F (2009) Involvement ofMembers of the Cadherin Superfamily in Cancer. Cold Spring Harbor Perspectives in Biology; 10.1101/cshperspect.a0031291.
26. Waha A, Felsberg J, Hartmann W, Von dem Knesebeck A, Mikeska T, et al. (2010) Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. Cancer Res 70: 1689-1699.
27. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2-deoxycytidine treatment and oligonucleotide microarray. Cancer Science 97: 64-71. 10.1111/j.1349-7006.2006.00136.x.
28. Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, et al. (2009) Discovery of Novel Hypermethylated Genes in Prostate Cancer Using Genomic CpG Island Microarrays. PLoS ONE 4: e4830. doi:10.1371/journal.pone.0004830.
29. Levy L, Hill CS (2006) Alterations in components of the TGF-β superfamily signaling pathways in human cancer. Cytokine & Growth Factor Reviews 17: 41-58.
30. Inman GJ (2011) Switching TGFβ from a tumor suppressor to a tumor promoter. Current Opinion in Genetics & Development 21: 93-99.
31. Garnis C, Coe BP, Zhang L, Rosin MP, Lam WL (2004) Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas. Oncogene 23: 2582-2586.
32. Helbing T, Volkmar F, Goebel U, Heinke J, Diehl P, et al. (2010) Krüppel-like factor 15 regulates BMPER in endothelial cells. Cardiovascular Research 85: 551-559.
33. Kelley R, Ren R, Pi X, Wu Y, Moreno I, et al. (2009) A concentration-dependent endocytic trap and sink mechanism converts Bmper from an activator to an inhibitor of Bmp signaling. The Journal of Cell Biology 184: 597-609.
34. Pinto M, Oliveira C, Cirnes L, Carlos Machado J, Ramires M, et al. (2003) Promoter methylation of TGFα receptor I and mutation of TGFα receptor II are frequent events in MSI sporadic gastric carcinomas. J Pathol 200: 32-38.
35. Chen G, Ghosh P, Osawa H, Sasaki CY, Rezanka L, et al. (2007) Resistance to TGF-α correlates with aberrant expression of TGF-α receptor II in human B-cell lymphoma cell lines. Blood 109: 5301-5307.
36. de Carvalho Fc, Colleoni GWB, Sampaio Almeida MS, Carvalho AL, Vettore AL (2009) TGFα R aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma. Int J Cancer 125: 1985-1991.
37. Shivapurkar N, Gazdar AF (2010) DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening. Current Molecular Medicine 10: 123-132.
38. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, et al. (2007) Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 28: 60-70.
39. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, et al. (2002) Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase and Survival of Patients With Diffuse Large B-Cell Lymphoma. J Natl Cancer Inst 94: 26-32.
40. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, et al. (2011) Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. Cancer Res 71: 3317-3327.
41. Iorns E, Turner NC, Elliott R, Syed N, Garrone O, et al. (2008) Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer. Cancer Cell 13: 91-104.
42. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, hado-Pinilla R, Rodriguez-Fanjul V, et al. (2010) IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29: 1681-1690.